EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate Production

Tomohiro Fujii, Yutaka Matsuda iD, Takuya Seki, Natsuki Shikida, Yusuke Iwai, Yuri Ooba, Kazutoshi Takahashi, Muneki Isokawa, Sayaka Kawaguchi, Noriko Hatada, Tomohiro Watanabe, Rika Takasugi und 5 weitere

Bioconjugate Chemistry · 09.03.2023

DOI: 10.1021/acs.bioconjchem.3c00040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, online erschienen am 09.03.2023. Verfasst von Tomohiro Fujii und 16 weiteren Autor:innen. Beteiligte Einrichtung: Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The site-directed chemical conjugation of antibodies remains an area of great interest and active efforts within the antibody-drug conjugate (ADC) community. We previously reported a unique site modification using a class of immunoglobulin-G (IgG) Fc-affinity reagents to establish a versatile, streamlined, and site-selective conjugation of native antibodies to enhance the therapeutic index of the resultant ADCs. This methodology, termed "AJICAP", successfully modified Lys248 of native antibodies to produce site-specific ADC with a wider therapeutic index than the Food and Drug Administration-approved ADC, Kadcyla. However, the long reaction sequences, including the reduction-oxidation (redox) treatment, increased the aggregation level. In this manuscript, we aimed to present an updated Fc-affinity-mediated site-specific conjugation technology named "AJICAP second generation" without redox treatment utilizing a "one-pot" antibody modification reaction. The stability of Fc affinity reagents was improved owing to structural optimization, enabling the production of various ADCs without aggregation. In addition to Lys248 conjugation, Lys288 conjugated ADCs with homogeneous drug-to-antibody ratio of 2 were produced using different Fc affinity peptide reagent possessing a proper spacer linkage. These two conjugation technologies were used to produce over 20 ADCs from several combinations of antibodies and drug linkers. The in vivo profile of Lys248 and Lys288 conjugated ADCs was also compared. Furthermore, nontraditional ADC production, such as antibody-protein conjugates and antibody-oligonucleotide conjugates, were achieved. These results strongly indicate that this Fc affinity conjugation approach is a promising strategy for manufacturing site-specific antibody conjugates without antibody engineering.

Autor:innen und Institutionen

  • Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.
  • Ajinomoto Bio-Pharma Services, 11040 Roselle Street, San Diego, California 92121, United States.

ORCID-Profile: Yutaka Matsuda, Brian A Mendelsohn

Zitieren

APA

Fujii, T., Matsuda, Y., Seki, T., Shikida, N., Iwai, Y., Ooba, Y., Takahashi, K., Isokawa, M., Kawaguchi, S., Hatada, N., Watanabe, T., Takasugi, R., Nakayama, A., Shimbo, K., Mendelsohn, B. A., Okuzumi, T., & Yamada, K. (2023). AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate Production. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.3c00040

Vancouver

Fujii T, Matsuda Y, Seki T, Shikida N, Iwai Y, Ooba Y, et al. AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate Production. Bioconjugate Chemistry. 2023. doi:10.1021/acs.bioconjchem.3c00040

BibTeX
@article{Fujii2023,
  author = {Fujii, Tomohiro and Matsuda, Yutaka and Seki, Takuya and Shikida, Natsuki and Iwai, Yusuke and Ooba, Yuri and Takahashi, Kazutoshi and Isokawa, Muneki and Kawaguchi, Sayaka and Hatada, Noriko and Watanabe, Tomohiro and Takasugi, Rika and Nakayama, Akira and Shimbo, Kazutaka and Mendelsohn, Brian A and Okuzumi, Tatsuya and Yamada, Kei},
  title = {AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate Production},
  journal = {Bioconjugate Chemistry},
  year = {2023},
  doi = {10.1021/acs.bioconjchem.3c00040}
}
Kostenlos starten →